Should I buy or sell Oxford Biomedica stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares. View OXB analyst ratings or view top-rated stocks .

What is Oxford Biomedica's stock price target for 2024?

4 brokers have issued twelve-month price targets for Oxford Biomedica's shares. Their OXB share price targets range from GBX 180 to GBX 1,010. On average, they expect the company's share price to reach GBX 498.75 in the next twelve months. This suggests a possible upside of 145.7% from the stock's current price. View analysts price targets for OXB or view top-rated stocks among Wall Street analysts .

How have OXB shares performed in 2024?

Oxford Biomedica's stock was trading at GBX 220 at the beginning of the year. Since then, OXB shares have decreased by 7.7% and is now trading at GBX 203. View the best growth stocks for 2024 here .

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ) , Petra Diamonds (PDL) , Sirius Minerals (SXX) , Centamin (CEY) , Lloyds Banking Group (LLOY) , Oxford Biomedica (OXBDF) , Premier Oil (PMO) , AFR.L (AFR) , Barclays (BARC) and Genel Energy (GENL) .

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:OXB

Oxford Biomedica (OXB) Share Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free OXB Stock Alerts

GBX 203

-2.00 (-0.98%)

(As of 04/19/2024 ET)

Compare

Today's Range: 200
▼
208
50-Day Range: 167.20
▼
215
52-Week Range: 164.29
▼
474.50

Volume: 184,107 shs
Average Volume: 225,806 shs
Market Capitalization: £202.92 million

P/E Ratio: N/A
Dividend Yield: 4.57%
Price Target: GBX 498.75

Stock Analysis Analyst Forecasts Chart Competitors Headlines Insider Trades

Get Oxford Biomedica alerts:

Oxford Biomedica MarketRank™ Stock Analysis

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 145.7% Upside
GBX 498.75 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.83 out of 5 stars

3.1

Analyst's Opinion

Consensus Rating
Oxford Biomedica has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Oxford Biomedica has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for OXB.

1.7

Dividend Strength

Dividend Leadership
Oxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Oxford Biomedica does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OXB.

3.2

News and Social Media Coverage

News Sentiment
Oxford Biomedica has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Oxford Biomedica this week, compared to 0 articles on an average week.
MarketBeat Follows
4 people have added Oxford Biomedica to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oxford Biomedica insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.19% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
58.10% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Oxford Biomedica is -317.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oxford Biomedica is -317.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oxford Biomedica has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Oxford Biomedica Stock (LON:OXB)

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

OXB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OXB Stock News Headlines

April 13, 2024 | americanbankingnews.com

Oxford Biomedica (LON:OXB) Share Price Crosses Above 200 Day Moving Average of $205.43

March 5, 2024 | finanznachrichten.de

Oxford BioMedica plc: Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 5, 2024 | finance.yahoo.com

Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results

February 5, 2024 | lse.co.uk

EnSilica hires new chief financial officer from Oxford Biomedica

January 29, 2024 | finance.yahoo.com

Oxford Biomedica completes acquisition of ABL Europe

December 19, 2023 | finance.yahoo.com

Oxford Biomedica (LON:OXB) shareholders have endured a 79% loss from investing in the stock three years ago

December 4, 2023 | msn.com

Oxford Biomedica inks deal to provide ‘footprint’ in EU market

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

December 4, 2023 | finance.yahoo.com

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO

October 22, 2023 | finance.yahoo.com

Oxford Biomedica's UK£39m Market Cap Fall Books Insider Losses

September 22, 2023 | finance.yahoo.com

Oxford Biomedica First Half 2023 Earnings: Misses Expectations

September 20, 2023 | finance.yahoo.com

Oxford BioMedica shares soar as vaccine maker raises earnings guidance

July 18, 2023 | finance.yahoo.com

Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook

May 25, 2023 | msn.com

RBC Capital Markets Reiterates Oxford Biomedica (LSE:OXB) Outperform Recommendation

May 15, 2023 | finance.yahoo.com

Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system

May 5, 2023 | finance.yahoo.com

Why Investors Shouldn't Be Surprised By Oxford Biomedica plc's (LON:OXB) Low P/S

April 26, 2023 | finance.yahoo.com

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

April 25, 2023 | markets.businessinsider.com

Oxford Biomedica Posts FY Loss

April 21, 2023 | marketwatch.com

2023-2030 "CGT CDMO Market" Share | Global Industry Analysis and Forecast

April 12, 2023 | marketwatch.com

2023-2030 Global CGT CDMO Market is Growing Rapidly with Modern Trend

March 26, 2023 | marketwatch.com

CGT CDMO Market Share and Forecast till 2030

March 15, 2023 | benzinga.com

Oxford BioMedica Stock (OTC:OXBDF), Quotes and News Summary

March 11, 2023 | finance.yahoo.com

As Oxford Biomedica plc's market cap (LON:OXB) drops to UK£484m, insiders might be questioning their decision to buy earlier this year

February 25, 2023 | marketwatch.com

What is a CAGR of CGT CDMO Market? CGT CDMO Market Value in 2028 with Competition Analysis Data of Top Key Players

February 22, 2023 | marketwatch.com

CGT CDMO Market Size Global Research Report, 2023 - 2028

January 30, 2023 | marketwatch.com

CGT CDMO Market Size 2023 Trend and Opportunities, Analysis, CAGR and Value Chain Study, Business Growth to 2028

See More Headlines

Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: LON:OXB
CUSIP: N/A
CIK: N/A
Web: www.oxfordbiomedica.co.uk
Phone: +44-1865-783000
Fax: N/A
Employees: 891
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: GBX 498.75
High Stock Price Target: GBX 1,010
Low Stock Price Target: GBX 180
Potential Upside/Downside: +146.9%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX (0.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-61,630,000.00
Net Margins: -51.78%
Pretax Margin: N/A
Return on Equity: -30.64%
Return on Assets: -12.05%

Debt

Debt-to-Equity Ratio: 57.10
Current Ratio: 3.32
Quick Ratio: 1.67

Sales & Book Value

Annual Sales: £119.02 million
Price / Sales: 1.70
Cash Flow: GBX 67.20 per share
Price / Cash Flow: 3.01
Book Value: GBX 178 per share
Price / Book: 1.13

Miscellaneous

Outstanding Shares: 99,960,000
Free Float: N/A
Market Cap: £201.95 million
Optionable: Not Optionable
Beta: 1.00

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Stuart Paynter (Age 52)
CFO & Director
Comp: $832k
Dr. Frank Mathias (Age 62)
CEO & Director
Mr. Thierry Cournez
COO & Site Head of UK Operations
Dr. James Miskin Ph.D.
Chief Quality & Technical Officer
Mr. Matthew Treagus
Chief Information Officer & Chief of Staff
Sophia Bolhassan
Head of Investor Relations
Ms. Natalie Louise Walter (Age 51)
General Counsel & Company Secretary
Ms. Lisa James
Chief People Officer
Dr. Kyriacos Mitrophanous Ph.D.
Chief Innovation Officer
Ms. Kati Hudson
Head of Intellectual Property and Contracts

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

OXB Stock Analysis - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares.
View OXB analyst ratings or view top-rated stocks.
What is Oxford Biomedica's stock price target for 2024?: 4 brokers have issued twelve-month price targets for Oxford Biomedica's shares. Their OXB share price targets range from GBX 180 to GBX 1,010. On average, they expect the company's share price to reach GBX 498.75 in the next twelve months. This suggests a possible upside of 145.7% from the stock's current price.
View analysts price targets for OXB or view top-rated stocks among Wall Street analysts.
How have OXB shares performed in 2024?: Oxford Biomedica's stock was trading at GBX 220 at the beginning of the year. Since then, OXB shares have decreased by 7.7% and is now trading at GBX 203.
View the best growth stocks for 2024 here.

What other stocks do shareholders of Oxford Biomedica own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).
How do I buy shares of Oxford Biomedica?: Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:OXB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oxford Biomedica (OXB) Share Price, News & Analysis

Oxford Biomedica MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Oxford Biomedica Stock (LON:OXB)

OXB Stock Price History

OXB Stock News Headlines

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

OXB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™